The efficacy and safety of different dosing frequency rhTPO in the treatment of postchemotherapy thrombocytopenia in acute leukemia patients

Objective:To evaluate the efficacy and safety of different dosing frequency recombinant human thrombopoietin(rhTPO) in the treatment of postchemotherapy thrombocytopenia in acute leukemia patients.Methods:Forty acute leukemia patients complicated with thrombocytopenia were randomly divided into the group A and group B.The group A were contiously treated with 15 000 U rhTPO,one time a day for 14 times,and the group B were treated with 15000 U rhTPO,one time two days for 7 times.The clinical effects and adverse reactions between two groups were compared.Results:After treatment,the level of platelet(PLT) in group A was significantly higher than that in group B(P<0.01).The duration time of PLT<50×10⁹/L,and the recovery time of PLT from 50×10⁹/L arriving at 75×10⁹/L or 100×10⁹/L in group A were significantly less than those in group B(P<0.01).No serious adverse events occurred in two groups.Conclusions:Compared with alternate-day dosing,the continuous dosing plays better enhancing effect in the PLT level.The difference of the reducing the risk of bleeding and medication safety between two groups is not obvious.